| Literature DB >> 33782623 |
Ana Rita Pombo Antunes1,2, Isabelle Scheyltjens1,2, Francesca Lodi3,4, Julie Messiaen5, Asier Antoranz5, Johnny Duerinck6, Daliya Kancheva7, Liesbet Martens8,9,10, Karen De Vlaminck1,2, Hannah Van Hove1,2, Signe Schmidt Kjølner Hansen1,2, Francesca Maria Bosisio11, Koen Van der Borght7, Steven De Vleeschouwer12,13, Raf Sciot11, Luc Bouwens14, Michiel Verfaillie15, Niels Vandamme16,17, Roosmarijn E Vandenbroucke18,9, Olivier De Wever19,20, Yvan Saeys16,17, Martin Guilliams8,9, Conny Gysemans21, Bart Neyns22, Frederik De Smet5, Diether Lambrechts3,4, Jo A Van Ginderachter1,2, Kiavash Movahedi23,24.
Abstract
Glioblastomas are aggressive primary brain cancers that recur as therapy-resistant tumors. Myeloid cells control glioblastoma malignancy, but their dynamics during disease progression remain poorly understood. Here, we employed single-cell RNA sequencing and CITE-seq to map the glioblastoma immune landscape in mouse tumors and in patients with newly diagnosed disease or recurrence. This revealed a large and diverse myeloid compartment, with dendritic cell and macrophage populations that were conserved across species and dynamic across disease stages. Tumor-associated macrophages (TAMs) consisted of microglia- or monocyte-derived populations, with both exhibiting additional heterogeneity, including subsets with conserved lipid and hypoxic signatures. Microglia- and monocyte-derived TAMs were self-renewing populations that competed for space and could be depleted via CSF1R blockade. Microglia-derived TAMs were predominant in newly diagnosed tumors, but were outnumbered by monocyte-derived TAMs following recurrence, especially in hypoxic tumor environments. Our results unravel the glioblastoma myeloid landscape and provide a framework for future therapeutic interventions.Entities:
Mesh:
Year: 2021 PMID: 33782623 DOI: 10.1038/s41593-020-00789-y
Source DB: PubMed Journal: Nat Neurosci ISSN: 1097-6256 Impact factor: 28.771